3.35 USD
▲-0.03+2.76%
2026-08-03
市值
$5.56M
市盈率
—
EPS
-40.15
股息率
—
52 周区间
3.12 – 71.50
成交量
58.44K
Beta
0.75
目标价
—
52W 低 3.1252W 高 71.50
价格走势
公司简介
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3...